case_images: PMC8166484_01
case_images: CT scan of the neck at presentation (axial image).
case_images: CRIE2021-5521649.001.jpg
case_images: PMC8166484_01_CRIE2021-5521649.001.jpg
case_images: fig1
case_images: CT scan of the neck showed a large, right thyroid lobe mass measuring 7.5 x 4.1 cm, displacing the larynx and trachea to the left and encasing the internal carotid artery by at least 180  (Figures 1 and 2 ). CT scans of the chest, abdomen, and pelvis and an MRI scan of the brain showed no definitive evidence of distant metastases.
case_images: CT scan of the neck at presentation (coronal image).
case_images: CRIE2021-5521649.002.jpg
case_images: PMC8166484_01_CRIE2021-5521649.002.jpg
case_images: fig2
case_images: CT scan of the neck showed a large, right thyroid lobe mass measuring 7.5 x 4.1 cm, displacing the larynx and trachea to the left and encasing the internal carotid artery by at least 180  (Figures 1 and 2 ). CT scans of the chest, abdomen, and pelvis and an MRI scan of the brain showed no definitive evidence of distant metastases.
case_images: Cytology showing atypical discohesive cells consistent with ATC.
case_images: CRIE2021-5521649.003.jpg
case_images: PMC8166484_01_CRIE2021-5521649.003.jpg
case_images: fig3
case_images: A repeat FNA biopsy of the right thyroid mass revealed discohesive atypical pleomorphic tumor cells consistent with ATC (Figure 3).
case_images: Immunocytochemistry staining showing strong positivity for PD-L1.
case_images: CRIE2021-5521649.004.jpg
case_images: PMC8166484_01_CRIE2021-5521649.004.jpg
case_images: fig4
case_images: PAX8, and negative for calcitonin, CEA, SOX-10, and p63. PD-L1 22C3 pharmDx:performed on Dako Autostainer Link 48:was positive for high PD-L1 expression with tumor proportion score (TPS) >95% (Figure 4).
case_images: First CT scan of the neck after the initiation of pembrolizumab, 4 doses (axial image).
case_images: CRIE2021-5521649.005.jpg
case_images: PMC8166484_01_CRIE2021-5521649.005.jpg
case_images: fig5
case_images: Restaging scans after four cycles of treatment (one cycle equaling three weeks) revealed a partial response per RECIST v 1.1 (48% decrease in the size of the tumor) (Figures 5 and 6 ).
case_images: First CT scan of the neck after the initiation of pembrolizumab, 4 doses (coronal image).
case_images: CRIE2021-5521649.006.jpg
case_images: PMC8166484_01_CRIE2021-5521649.006.jpg
case_images: fig6
case_images: Restaging scans after four cycles of treatment (one cycle equaling three weeks) revealed a partial response per RECIST v 1.1 (48% decrease in the size of the tumor) (Figures 5 and 6 ).
case_images: CT scan of the neck after 25 doses of pembrolizumab (axial image).
case_images: CRIE2021-5521649.007.jpg
case_images: PMC8166484_01_CRIE2021-5521649.007.jpg
case_images: fig7
case_images: The patient has received 25 doses of pembrolizumab with continued reduction in size of tumor with most recent scans performed showing approximately 66% reduction in tumor from pretherapy (Figures 7 and 8 ).
case_images: CT scan of the neck after 25 doses of pembrolizumab (coronal image).
case_images: CRIE2021-5521649.008.jpg
case_images: PMC8166484_01_CRIE2021-5521649.008.jpg
case_images: fig8
case_images: The patient has received 25 doses of pembrolizumab with continued reduction in size of tumor with most recent scans performed showing approximately 66% reduction in tumor from pretherapy (Figures 7 and 8 ).